NCT00536172View on ClinicalTrials.gov

Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

December 1, 2007

Primary Completion Date

June 1, 2012

Study Completion Date

June 1, 2012

Conditions
Depression
Interventions
DRUG

Escitalopram

Participants take 10 mg for 1 week and then 20 mg for 15 weeks.

DRUG

Placebo

Placebo distribution matches the active medication.

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Nebraska

OTHER

NCT00536172 - Evaluating the Effectiveness of Escitalopram to Prevent Depression in Head and Neck Cancer Patients Receiving Treatment | Biotech Hunter | Biotech Hunter